JNJ
Johnson & Johnson · Healthcare · Drug Manufacturers - General
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 12.70M | $3.29B | n/a | n/a |
| Q2 2026 | 181 | +1 | 1.42B | $361.32B | +5 | −5 |
| Q1 2026 | 184 | 0 | 1.43B | $348.29B | +4 | −5 |
| Q4 2025 | 183 | 0 | 1.52B | $314.40B | +2 | −1 |
| Q3 2025 | 28 | 0 | 887.20M | $164.46B | n/a | −1 |
| Q2 2025 | 26 | +1 | 740.96M | $113.15B | +1 | n/a |
| Q1 2025 | 22 | -1 | 281.15M | $46.60B | n/a | −1 |
| Q4 2024 | 23 | +3 | 290.64M | $42.01B | +3 | n/a |
| Q3 2024 | 19 | -2 | 157.55M | $25.50B | n/a | −2 |
| Q2 2024 | 21 | n/a | 161.11M | $23.53B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 55.10M | n/a | $8.03B | 0.7% | n/c | 1 | SEC ↗ ×2 |
| 2 | Norges Bank ✦ (passive) | 29.09M | n/a | $4.25B | 0.6% | n/c | 1 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 24.91M | n/a | $3.64B | 0.4% | n/c | 1 | SEC ↗ ×2 |
| 4 | Wellington Management ✦ | 24.85M | n/a | $3.63B | 0.7% | n/c | 1 | SEC ↗ ×7 |
| 5 | Fisher Asset Management ✦ | 7.01M | n/a | $1.02B | 0.4% | n/c | 1 | SEC ↗ |
| 6 | Marshall Wace ✦ | 3.88M | n/a | $567.83M | 0.8% | n/c | 1 | SEC ↗ ×2 |
| 7 | AQR Capital Management ✦ | 3.35M | n/a | $489.18M | 0.8% | n/c | 1 | SEC ↗ ×5 |
| 8 | Bridgewater Associates ✦ | 3.20M | n/a | $468.34M | 2.4% | n/c | 1 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 1.53M | n/a | $223.58M | 0.4% | n/c | 1 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 1.46M | n/a | $212.68M | 0.2% | n/c | 1 | SEC ↗ ×2 |
| 11 | D. E. Shaw & Co. ✦ | 1.16M | n/a | $170.12M | 0.3% | n/c | 1 | SEC ↗ ×2 |
| 12 | Tweedy, Browne ✦ | 1.13M | n/a | $165.23M | 7.6% | n/c | 1 | SEC ↗ |
| 13 | Millennium Management ✦ | 1.08M | n/a | $157.41M | 0.1% | n/c | 1 | SEC ↗ |
| 14 | Adage Capital Partners ✦ | 852.52K | n/a | $124.60M | 0.2% | n/c | 1 | SEC ↗ |
| 15 | Arrowstreet Capital ✦ | 828.12K | n/a | $121.04M | 0.1% | n/c | 1 | SEC ↗ |
| 16 | Two Sigma Investments ✦ | 649.75K | n/a | $94.97M | 0.2% | n/c | 1 | SEC ↗ |
| 17 | Markel Group ✦ | 610.80K | n/a | $89.27M | 0.9% | n/c | 1 | SEC ↗ ×2 |
| 18 | Gotham Asset Management ✦ | 218.02K | n/a | $31.87M | 0.4% | n/c | 1 | SEC ↗ |
| 19 | GAMCO Investors ✦ | 98.36K | n/a | $14.38M | 0.2% | n/c | 1 | SEC ↗ |
| 20 | Fairfax Financial ✦ | 73.40K | n/a | $10.72M | 0.9% | n/c | 1 | SEC ↗ |
| 21 | Dodge & Cox ✦ | 21.10K | n/a | $3.08M | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 136.10K shares, $33,268 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 11.07K sh · $3.04M
Officer · 22.53K sh · $6.19M
Officer · 15.00K sh · $3.95M
Officer, Director · 102.31K sh · $26.70M
Officer, Director · 20.98K sh · $5.50M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology